Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.

Ka-Po FungKei-Hong ChanVivien NgPing-Tim TsuiJoyce Hoi-Sze You

Published in: Cardiovascular drugs and therapy (2020)

Total direct cost and LOS for VTE admission and total cost in 1-year post-discharge period were significantly lower in patients initiated and discharged with rivaroxaban than those of warfarin.

Keyphrases

venous thromboembolism
direct oral anticoagulants
end stage renal disease
atrial fibrillation
newly diagnosed
healthcare
ejection fraction
chronic kidney disease
public health
emergency department
mental health
prognostic factors
risk assessment
health information
social media
patient reported